Balasa Dinverno & Foltz LLC boosted its position in Rockwell Medical, Inc. (NASDAQ:RMTI) by 5.8% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 54,300 shares of the company’s stock after buying an additional 3,000 shares during the period. Balasa Dinverno & Foltz LLC owned about 0.10% of Rockwell Medical worth $431,000 as of its most recent SEC filing.
Several other large investors have also recently modified their holdings of RMTI. Wells Fargo & Company MN boosted its stake in shares of Rockwell Medical by 0.5% in the first quarter. Wells Fargo & Company MN now owns 115,738 shares of the company’s stock valued at $725,000 after buying an additional 550 shares during the period. Geneva Advisors LLC boosted its stake in shares of Rockwell Medical by 3.7% in the first quarter. Geneva Advisors LLC now owns 20,970 shares of the company’s stock valued at $131,000 after buying an additional 750 shares during the period. American International Group Inc. boosted its stake in shares of Rockwell Medical by 7.1% in the first quarter. American International Group Inc. now owns 29,509 shares of the company’s stock valued at $185,000 after buying an additional 1,955 shares during the period. State Street Corp boosted its stake in shares of Rockwell Medical by 0.3% in the fourth quarter. State Street Corp now owns 878,759 shares of the company’s stock valued at $5,754,000 after buying an additional 2,523 shares during the period. Finally, Teachers Advisors LLC boosted its stake in shares of Rockwell Medical by 5.3% in the fourth quarter. Teachers Advisors LLC now owns 78,948 shares of the company’s stock valued at $517,000 after buying an additional 4,000 shares during the period. Institutional investors own 20.54% of the company’s stock.
Shares of Rockwell Medical, Inc. (RMTI) traded up 0.527% on Tuesday, reaching $6.675. 98,376 shares of the company’s stock traded hands. The firm’s market cap is $347.48 million. Rockwell Medical, Inc. has a one year low of $3.55 and a one year high of $8.98. The company’s 50-day moving average price is $7.75 and its 200 day moving average price is $6.87.
Rockwell Medical (NASDAQ:RMTI) last announced its quarterly earnings results on Tuesday, May 9th. The company reported ($0.09) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.09). Rockwell Medical had a negative net margin of 36.35% and a negative return on equity of 36.36%. The firm had revenue of $14.60 million during the quarter, compared to the consensus estimate of $12.66 million. During the same period last year, the firm earned ($0.10) EPS. The business’s quarterly revenue was up 7.4% compared to the same quarter last year. On average, equities analysts forecast that Rockwell Medical, Inc. will post ($0.39) EPS for the current fiscal year.
WARNING: “Balasa Dinverno & Foltz LLC Has $431,000 Stake in Rockwell Medical, Inc. (NASDAQ:RMTI)” was posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://stocknewstimes.com/2017/08/08/balasa-dinverno-foltz-llc-has-431000-stake-in-rockwell-medical-inc-nasdaqrmti-updated.html.
Several equities research analysts recently issued reports on the company. BidaskClub cut Rockwell Medical from a “sell” rating to a “strong sell” rating in a research note on Saturday. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, April 11th. Finally, ValuEngine cut Rockwell Medical from a “hold” rating to a “sell” rating in a research note on Friday, June 2nd. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and one has given a buy rating to the stock. Rockwell Medical has a consensus rating of “Hold” and a consensus price target of $7.50.
About Rockwell Medical
Rockwell Medical, Inc (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
